“Without Labcorp, Burlington would be really, really struggling," David King, former CEO of the Triad-based global life sciences giant, said.
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
David King, who led Labcorp from a tumultuous time to becoming a Triangle juggernaut, was honored in a lively event as life science leaders packed a ballroom to listen to an industry icon.